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induced hemostatic dysfunction is related in part to
platelet dysfunction,3 platelet transfusion therapy has
been a major component in the management of bleed-
T he institution of cardiopulmonary bypass (CPB)elicits a hemostatic defect that leads to increased
blood loss after cardiac operations.1,2 Because the CPB-
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ing after CPB. The current method of liquid storage of
platelets at room temperature limits the duration of
their clinical use to 5 days and results in a progressive
decline in platelet survival during this period.4
Cryopreservation, which allows storage of the platelets
for as long 2 years, represents an alternative strategy for
maintaining an adequate inventory of platelets. Cryo-
preserved platelets have reduced recovery and survival
in vivo and impaired response to in vitro testing com-
pared with liquid-preserved platelets.5-9 However,
platelet recovery and survival in vivo do not correlate
with the in vivo hemostatic function of transfused
platelets.10 Cryopreserved platelet transfusions have
demonstrated therapeutic effectiveness6,11 but have not
been reported on in the setting of CPB. No randomized
trials in any clinical setting have addressed the in vivo
hemostatic effectiveness of cryopreserved platelet
transfusions compared with that of liquid-preserved
platelet transfusions.
The CPB-induced hemostatic defect offers a unique
opportunity for the assessment of the hemostatic effec-
tiveness in vivo of specific interventions because it
results in postoperative blood loss, a quantifiable vari-
able that relates directly to the magnitude of the CPB-
induced hemostatic dysfunction.1 This paradigm has
been effectively employed in numerous studies that
have demonstrated the hemostatic efficacy of pharma-
cologic agents, such as aprotinin, by demonstrating
their efficacy in reducing blood loss after CPB.12 This
study was designed to assess the comparative effects on
hemostasis and blood loss of liquid-preserved and cry-
opreserved platelet transfusions obtained from healthy
volunteers and administered to patients after complex
cardiac operations. The study also provides a compari-
son between the in vivo hemostatic effect and the in
vitro function of both liquid-preserved and cryopre-
served platelet transfusions.
Methods
Study protocol. After institutional review board approval
was obtained, this investigation was performed on 73 patients
undergoing cardiac operations at the West Roxbury Veterans
Administration Medical Center. Informed consent was
obtained from patients scheduled to undergo 1 of a predefined
list of complex cardiac surgical procedures. Inclusion criteria
were as follows:
1. Patient was scheduled for reoperative valve replace-
ment, reoperative coronary artery bypass grafting, or both.
2. Patient was scheduled for primary valve replacement
combined with coronary artery bypass grafting.
3. Valve replacement was scheduled for a patient with a
platelet count of ≤150,000/m L.
4. An operation with CPB was to be performed on a
patient with a preoperative intra-aortic balloon pump and a
platelet count ≤100,000/m L.
These operations were chosen because they were anticipat-
ed to require a prolonged period of CPB and also because a
review of the institution’s previous experience had revealed a
high likelihood of their resulting in platelet transfusions. The
operations were performed by 2 surgeons (S.F.K. and V.B.)
employing a similar technique for CPB under moderate sys-
temic hypothermia. A centrifugal pump and a membrane oxy-
genator were used in the circuit. No prophylactic antifibri-
nolytic therapy (eg, aprotinin, e -aminocaproic acid) was
administered. Systemic anticoagulation was achieved with an
initial heparin dose of 3 mg/kg body weight and maintained
with the activated clotting time (ACT) during CPB longer
than 480 seconds. After weaning from CPB and decannula-
tion, heparin was neutralized with protamine sulfate given in
a ratio of 0.5 mg of protamine to 1.0 mg of the initial heparin
dose and 1.0 mg of protamine to 1.0 mg of heparin for any
subsequent doses. Reversal of the heparin effect was deter-
mined by the return of the ACT to baseline level. At this time
measurement of the blood loss was started, and the platelet
transfusion previously determined by the randomization
process was given unless the magnitude of the diffuse oozing
from the tissues was determined by the surgeon to be mini-
mal. Throughout both the intraoperative and postoperative
courses, the surgeon, the anesthesiologist, and all individuals
involved with ordering blood products during the patient’s
postoperative course were kept blinded to the type of platelets
randomly selected for transfusion. The need for transfusion
of red blood cells, fresh-frozen plasma, or further platelets
was determined by the house staff after consultation with the
attending surgeon, in accordance with set protocols that
involved the observed blood loss and the patient’s hemoglo-
bin, hematocrit, and prothrombin time. A record was kept of
all blood products received after CPB including unwashed
shed mediastinal blood that was collected in the chest tube
Pleur-evac collecting system (Deknatel, Inc, Fall River,
Mass) and routinely reinfused in all patients.
Measurement of postoperative blood loss. Measurement of
blood loss was started in the operating room when the ACT
returned to baseline after the administration of protamine. In
the absence of specific localized surgical bleeding, the gener-
alized blood loss after the neutralization of heparin was
assumed to be reflective of the patient’s hemostatic state and
was termed nonsurgical blood loss. To ensure that the blood
measured represented nonsurgical blood loss, patients in
whom specific surgical bleeding was encountered after the
neutralization of heparin were prospectively excluded from
the analysis. In addition, fluid irrigation was avoided during
the closure of the chest so as not to interfere with the weight
of the sponges. If irrigation was necessary, the fluid used was
aspirated separately and sponges were not used during the
irrigation. In the postoperative period, patients who had to
undergo reexploration for control of bleeding were also
excluded from the analysis.
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A dedicated research assistant measured the blood loss
starting from the time of the neutralization of heparin. This
included all the blood aspirated from the surgical field
through wall suction and through a Cell Saver apparatus
(Haemonetics Corp, Braintree, Mass). It also included the
blood contained in the sponges and laparotomy pads used in
the operative field. These were accurately weighed and their
blood content was calculated by subtracting the standardized
dry weights from the actual wet weights. The differences in
the weight of the sponges and pads were converted into mil-
liliters of blood loss in accordance with the formula described
by Van Slyke and associates.13
Chest tube drainage was measured as soon as the chest
tubes were placed during the operation, and this measurement
was continued until the patient was transferred out of the
operating room. The blood loss measured to this point con-
stituted the intraoperative component of the blood loss.
Subsequent chest drainage in the surgical intensive care unit
constituted the postoperative component of the blood loss.
Platelet products. All donors met the requirements of the
American Association of Blood Banks for healthy donors.
Cryopreserved platelets. The platelet cryopreservation
method has been previously described elsewhere.6 It is sum-
marized in the Appendix. The total length of storage (mean
289 ± 193 days) at –80°C of the frozen platelets is shown in
Fig 1. The mean in vitro platelet recovery after thawing, wash-
ing, and resuspension of the 68 units transfused to patients, as
determined by phase microscopy, was 70% ± 18.4%.
Liquid-preserved platelets. Two types of liquid-preserved
platelets were used in this study, pooled platelets and platelets
obtained by apheresis. The methods of preparation of these
platelets are described in the Appendix. Patients randomly
assigned to receive liquid-preserved platelets received either
type of platelet transfusion according to the availability in the
blood bank.
Recovery of transfused platelets. The total number of
platelets transfused was determined by multiplying the vol-
ume of the product transfused times the product’s platelet
count per milliliter. The patient’s blood volume was estimat-
ed from the body surface area, and peripheral blood platelet
count was measured with the Coulter model JT automated
cell-counting system (Coulter Electronics, Hialeah, Fla). The
total platelet increment after transfusion at each time interval
was determined by the increase in the absolute peripheral
blood platelet count compared with the pretransfusion value
times the total blood volume. The percentage recovery of the
transfused platelets was determined by the total increment
divided by the total number of platelets transfused.
Recovery (%) = [(Total blood volume [Posttransfusion platelet
count/mL – Pretransfusion platelet count/mL]) / (Total
number of platelets transfused)] · 100%
Hematologic assays. Arterial blood was drawn into tri-
potassium ethylenediaminetetraacetic acid–containing tubes
for measurement of hematocrit, hemoglobin, platelet count,
white blood cell count, and mean platelet volume with an
electronic particle counter (Coulter model JT)14; and into
sodium citrate–containing tubes for measurement of fibrino-
gen, factor V, and factor VIII with an automated coagulation
system (Organon Teknika Corp, Durham, NC),15 of fibro-
nectin by an immunoturbidometric assay,16 of heparin by a
chromogenic assay,17 and of D-dimer by an enzyme-linked
immunosorbent assay.18 Serum was obtained from a tube
containing no anticoagulant for measurement of albumin
measured using an automated chemistry analyzer (Cobas;
Roche Diagnostic Systems, Inc, Branchburg, NJ).19
Fig 1. Number of platelet transfusions administered and length of storage (days) of liquid-preserved pooled
platelets at 22°C, liquid-preserved apheresed platelets at 22°C, and cryopreserved platelets at –80°C.
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Blood samples were withdrawn at the following time
points: (1) immediately before heparin administration, (2) 5
minutes after heparin administration, (3) 40 minutes after the
start of CPB, (4) after the administration of protamine and
return of the ACT to prebypass levels (post-CPB), (5) 30 min-
utes after platelet transfusion, (6) 2 hours after platelet trans-
fusion, (7) 4 hours after platelet transfusion, and (8) 24 hours
after platelet transfusion. A standard template bleeding time
was also performed at all the study times.20 Skin temperature
at the site of the determination of the bleeding time was
recorded with every bleeding time measurement.21 A volume
of 0.6 mL blood shed from the template bleeding time site
was aspirated and assayed for thromboxane B2, the stable
metabolite of thromboxane A2; this is referred to henceforth
as shed blood thromboxane B2. The assay employed has been
described previously elsewhere.21
Some of the hematologic measurements were made only in
a portion of the total study population. These measurements
and the numbers of randomly assigned patients in the 2 sub-
groups are as follows: shed blood thromboxane B2, 21 with
cryopreserved platelets and 19 with liquid-preserved platelets;
albumin, 9 with cryopreserved platelets and 11 with liquid-pre-
served platelets; fibrinogen, 10 with cryopreserved platelets
and 14 with liquid-preserved platelets; fibronectin, 8 with cry-
opreserved platelets and 6 with liquid-preserved platelets; fac-
tor V, 7 with cryopreserved platelets and 11 with liquid-pre-
served platelets; factor VIII, 5 with cryopreserved platelets and
10 with liquid-preserved platelets; and D-dimer, 11 with cry-
opreserved platelets and 15 with liquid-preserved platelets.
Platelet function studies. Platelet aggregation in response
to arachidonic acid (AA) and adenosine diphosphate (ADP),
thromboxane B2 levels, platelet recovery from hypotonic
stress, plasma pH, and procoagulant activity were measured
in the various types of platelets administered in accordance
with the methods summarized in the Appendix.
Statistical analysis. Differences between the 2 groups in the
preoperative patient characteristics, the baseline hematologic
parameters, and the postoperative clinical events were assessed
by the Student t test for continuous variables and the c 2 test for
dichotomous variables. The effects of platelet transfusion on
the parameters assayed at 30 minutes, and at 2, 4, and 24 hours
after transfusion were assessed by a 2-way repeated measures
analysis of variance. In the case of platelet increment, platelet
survival, shed blood thromboxane B2, and D-dimer, a nonpara-
metric repeated measures analysis of variance with treatment
and time as factors (Friedman’s method) was used. A P value
was calculated for an overall difference through time between
the 2 patient groups. The Wilcoxon rank test was used to assess
differences in blood loss between the groups.
Results
Seventy-three patients were entered into the study and
randomly assigned to receive either liquid-preserved or
cryopreserved platelets. Twenty patients were excluded
from the study after random assignment. The reasons
for exclusion were as follows: 6 patients had minimal
diffuse oozing after protamine administration and were
deemed by the surgeon not to require platelet transfu-
sions, 6 patients had a documented site of surgical
bleeding after the administration of protamine (3
received cryopreserved platelets and 3 received liquid-
preserved platelets), and 5 patients (7%) died within 24
hours after the institution of CPB for reasons not relat-
ed to the platelet transfusions (3 received no platelets, 1
received cryopreserved platelets, and 1 received liquid-
preserved platelets). Three patients (2 receiving cryop-
reserved platelets and 1 receiving liquid-preserved
platelets) had e -aminocaproic acid (Amicar) inadver-
tently administered during the immediate postoperative
period. The mortality rate for all patients undergoing
Table I. Patient characteristics
Liquid-preserved Cryopreserved 
(n = 29) (n = 24) P
Age (y) 62.9 ± 8.0 63.4 ± 8.1 >.2
Preoperative hematocrit (%) 33.6 ± 5.0 34.8 ± 4.7 .20
Preoperative bleeding time (min) 6.8 ± 2.8 6.9 ± 3.2 >.2
Preoperative ejection fraction (%) 52 ± 13 55 ± 16 >.2
Preoperative prothrombin time (s) 14.1 ± 7.0 13.2 ± 3.4 >.2
Preoperative partial thromboplastin time (s) 36.5 ± 19.1 33.8 ± 14.2 >.2
Platelet count (103 cells/mm3) 199 ± 77 179 ± 53 .19
Operation performed (no. of patients)
Primary CABG* 1 4
Reoperative CABG 10 11
Primary valve replacement, with or without CABG 12 6
Reoperative valve replacement, with or without CABG 3 1
Primary valve replacement, with or without other 3 2
CPB time (min) 177 ± 64 155 ± 69 .12
Lowest temperature during CPB (°C) 31.3 ± 3.9 30.5 ± 3.8 >.2
Data are expressed as mean ± SD. CABG, Coronary artery bypass grafting.
*Originally scheduled for coronary artery bypass grafting and valve replacement; during the operation a decision was made not to replace the valve.
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cardiac operations during the study period was 3.8%.
Final data analysis was therefore performed on 53
patients, 24 of whom received cryopreserved platelets
and 29 of whom received liquid-preserved platelets. In
the group of 29 receiving the liquid-preserved platelets,
10 patients received 7 to 10 random donor platelet con-
centrates (pooled), 15 patients received apheresis
platelets, and 4 patients received both random donor
platelet concentrates and apheresis platelets.
Patient characteristics and outcomes. The preoper-
ative patient characteristics are shown in Table I. All
patients were men undergoing complex cardiac opera-
tions with prolonged crossclamp and CPB times. None
of the patients had received aspirin or antiplatelet agents
within 1 week before the operation. Patient characteris-
tics and hematocrit, platelet count, bleeding time, pro-
thrombin time, and partial thromboplastin time did not
differ significantly between the 2 groups before CPB
(Table I). Within the liquid-preserved patient group
there were no significant differences in these parameters
between those who received apheresed platelet transfu-
sions and those who received pooled platelet transfu-
sions. Four patients, 2 in each group, received an intra-
aortic balloon pump before operation. An additional 6
patients had an intra-aortic balloon pump placed either
during the operation (2 in each group) or after the oper-
ation (1 in each group).
In both groups no clinical reactions were observed
after the infusion of the platelets or other blood prod-
ucts. The incidences of thromboembolic complications
and infections (wound infection, pneumonia) did not
differ statistically between the 2 groups. The duration of
tracheal intubation was significantly (P = .04) longer in
the patients who received the liquid-preserved platelets
than in the patients who received the cryopreserved
platelet transfusions (31.7 ± 25.4 and 23.2 ± 15.6 hours,
respectively).
Characteristics and hematologic effects of trans-
fused platelets. The characteristics of the platelet trans-
fusions in the liquid-preserved group are shown in Table
II. The liquid-preserved apheresed platelets were trans-
fused in smaller numbers and in lesser volumes. The
characteristics of the transfused platelets used in the 2
patient groups are shown in Table III. The storage time
before transfusion for cryopreserved platelets was 289 ±
193 days, compared with 3.4 ± 1.1 days for liquid-pre-
served platelets (P < .0001). More than 50% of the liq-
uid-preserved platelet transfusions were stored for 4 to
5 days before administration (Fig 1). The duration of
storage was not different between the liquid-preserved
pooled platelets and the liquid-preserved apheresed
platelets. The shortest period of cryopreservation was
30 days and the longest was 2 years (Fig 1). A signifi-
cantly higher number of platelets was administered with
the liquid-preserved transfusions than with the cryopre-
served transfusions (Table III).
Table IV lists the values of the hematologic parame-
ters measured in the 2 patient groups before CPB and
at designated time points after the complete adminis-
tration of the platelets. There were no differences
before CPB between the 2 groups in any of the vari-
ables listed in Table IV. The hematocrit during the first
Table II. Comparison of characteristics of liquid-preserved pooled versus apheresed platelet transfusions
Pooled units Apheresis units P
Age (d)
Mean 3.27 ± 0.87 3.43 ± 1.17 >.2
Median 3.0 4.0
Range 2-5 2-5
Volume of platelets transfused per patient (mL) 669 ± 292 346 ± 166 .005
No. of platelets transfused per patient (1011 cells) 9.17 ± 4.3 5.19 ± 2.3 .01
Data are expressed as mean ± SD.
Table III. Comparison of characteristics of liquid-preserved versus cryopreserved platelet transfusions
Liquid-preserved Cryopreserved P
Age (d)
Mean 3.4 ± 1.1 289 ± 193 .0001
Median 3.8 250
Range 2-5 30-720
Volume of platelets transfused/patient (mL) 487 ± 278 184 ± 96 .0001
No. of platelets transfused per patient (1011 cells) 6.9 ± 3.9 4.5 ± 2.1 .008
Data are expressed as mean ± SD.
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4 hours after transfusion was significantly higher in the
patients receiving the cryopreserved platelets. The
platelet count and the mean platelet volume were not
significantly different between the 2 patient groups, but
the platelet increment after transfusion was significantly
lower in the patients receiving the cryopreserved
platelet transfusions than in those receiving the liquid-
preserved platelet transfusions. The decrease in platelet
increment was associated with an indeterminate
decrease in platelet survival in the cryopreserved
platelet group (P = .071). This latter decrease might
have achieved statistical significance with a larger
patient cohort. The postoperative bleeding times and
skin temperature at the site of the bleeding time deter-
Table IV. In vivo effects of transfused platelets
After platelet transfusion
Before CPB 30 min 2 h 4 h 24 h
Mean ± SD n P* Mean ± SD n Mean ± SD n Mean ± SD n Mean ± SD n P†
Hematocrit (%) >.2 .027
Liquid-preserved 33.7 ± 5.0 28 27.5 ± 3.9 22 29.5 ± 4.0 13 28.3 ± 3.9 13 29.2 ± 3.4 12
Cryopreserved 34.8 ± 4.8 24 31.7 ± 6.3 21 34.2 ± 5.5 24 31.7 ± 5.2 24 28.8 ± 3.8 23
Platelet count (106 cells/mL) >.2 >.2
Liquid-preserved 199 ± 77 27 162 ± 62 26 152 ± 61 29 150 ± 56 29 138 ± 52 24
Cryopreserved 179 ± 53 23 122 ± 33 21 127 ± 41 24 124 ± 42 23 155 ± 207 23
Mean platelet volume (m m3) >.2 >.2
Liquid-preserved 9.5 ± 1.4 21 8.9 ± 1.1 21 9.3 ± 1.1 21 9.5 ± 1.4 21 9.3 ± 0.9 17
Cryopreserved 9.2 ± 0.9 19 8.9 ± 1.2 17 9.0 ± 1.0 19 9.1 ± 0.9 19 9.2 ± 1.0 18
Platelet increment (108 cells) .021‡
Liquid-preserved 2.5 ± 2.2 24 2.3 ± 2.3 27 2.2 ± 2.2 27 1.8 ± 1.6 22
Cryopreserved 0.8 ± 1.1 20 1.3 ± 1.4 24 0.9 ± 1.3 24 0.7 ± 1.2 24
Platelet survival (%) .071‡
Liquid-preserved 36.8 ± 26.0 21 37.2 ± 35.4 26 33.5 ± 31.7 26 30.6 ± 29.8 22
Cryopreserved 16.9 ± 22.7 19 23.6 ± 27.8 22 21.8 ± 28.7 23 13.4 ± 19.1 24
Bleeding time (min) >.2 >.2
Liquid-preserved 6.8 ± 2.8 27 10.8 ± 4.1 25 10.9 ± 4.1 28 10.0 ± 4.4 28 7.4 ± 2.6 23
Cryopreserved 6.9 ± 3.2 23 10.7 ± 3.2 21 10.3 ± 4.1 22 9.5 ± 3.7 23 7.7 ± 3.5 22
Skin temp at bleeding time site (°C) >.2 >.2
Liquid-preserved 29.4 ± 1.2 27 30.2 ± 1.8 28 30.1 ± 1.8 28 30.6 ± 1.7 29 31.7 ± 2.0 23
Cryopreserved 29.3 ± 1.8 23 30.3 ± 2.1 22 30.1 ± 2.0 23 30.5 ± 2.9 22 30.7 ± 1.8 20
Shed blood TXB2 (pg/0.1 mL) >.2 .068‡
Liquid-preserved 825 ± 840 11 319 ± 237 11 330 ± 234 12 397 ± 385 13 647 ± 621 12
Cryopreserved 996 ± 719 14 654 ± 859 13 440 ± 245 15 612 ± 464 15 1080 ± 1147 11
Plasma fibrinogen (mg/dL) .13 .024
Liquid-preserved 333 ± 99 13 191 ± 35 9 192 ± 44 11 187 ± 46 11 321 ± 84 7
Cryopreserved 416 ± 166 8 262 ± 86 7 291 ± 110 8 290 ± 105 8 427 ± 126 9
Serum albumin (g/dL) >.2 >.2
Liquid-preserved 3.26 ± 0.43 11 2.49 ± 0.46 9 2.79 ± 0.53 10 2.73 ± 0.59 10 2.87 ± 0.66 9
Cryopreserved 3.15 ± 0.30 8 2.58 ± 0.63 9 3.09 ± 0.61 10 3.26 ± 0.77 10 3.14 ± 0.54 9
Factor V in plasma (%) >.2 .166
Liquid-preserved 67.5 ± 19.1 10 22.4 ± 6.9 10 22.9 ± 4.0 11 28.2 ± 8.5 10 42.3 ± 15.5 10
Cryopreserved 72.6 ± 21.4 7 25.7 ± 15.1 6 26.1 ± 12.1 8 30.7 ± 10.0 8 69.0 ± 32.2 7
Factor VIII in plasma (%) .15 .125
Liquid-preserved 115 ± 36 11 54 ± 23 10 59 ± 24 12 63 ± 25 11 118 ± 56 9
Cryopreserved 128 ± 12 7 64 ± 26 7 77 ± 28 8 93 ± 46 8 168 ± 87 8
Plasma fibronectin (m g/dL) >.2 >.2
Liquid-preserved 384 ± 162 9 234 ± 88 8 223 ± 85 10 204 ± 92 10 196 ± 57 9
Cryopreserved 342 ± 74 10 228 ± 51 8 236 ± 57 10 221 ± 44 10 221 ± 44 10
Plasma D-dimer (m g/dL) >.2 >.2‡
Liquid-preserved 616 ± 282 12 2602 ± 1449 11 3333 ± 1203 12 4565 ± 4155 12 3381 ± 2176 8
Cryopreserved 1011 ± 1258 8 3311 ± 1942 9 4320 ± 2225 10 6928 ± 4967 10 1647 ± 548 7
temp, Temperature.
*Significance of t test between the 2 groups at baseline.
†Significance between the 2 groups by repeated measures parametric analysis of variance (30 minutes and 2, 4, and 24 hours).
‡Significance between the groups by nonparametric analysis of variance (Friedman test).
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Table V. In vivo effects of transfused liquid-preserved platelets
After platelet transfusion
Before CPB 30 min 2 h 4 h 24 h
Mean ± SD n P* Mean ± SD n Mean ± SD n Mean ± SD n Mean ± SD n P†
Hematocrit (%) >.2 >.2
Pooled 33.7 ± 4.2 10 27.1 ± 3.3 9 29.6 ± 4.9 6 26.2 ± 3.3 6 29.6 ± 2.5 5
Apheresis 33.3 ± 5.3 14 28.8 ± 3.7 14 30.1 ± 1.4 4 29.3 ± 2.6 4 28.6 ± 2.1 4
Platelet count (106 cells/mL) >.2 >.2
Pooled 191 ± 66 10 196 ± 62 9 180 ± 62 10 180 ± 67 10 167 ± 37 9
Apheresis 197 ± 73 13 150 ± 61 14 142 ± 61 15 136 ± 49 15 127 ± 53 11
Mean platelet volume (m m3) >.2 >.2
Pooled 9.2 ± 1.1 7 8.7 ± 0.8 8 9.3 ± 1.0 8 9.3 ± 0.9 8 9.2 ± 0.9 8
Apheresis 9.6 ± 1.7 11 9.2 ± 1.3 11 9.5 ± 1.2 10 9.7 ± 1.8 10 9.4 ± 1.0 6
Platelet increment (108 cells) >.2
Pooled 3.8 ± 2.3 8 3.3 ± 2.7 10 3.4 ± 2.7 9 2.2 ± 1.8 8
Apheresis 2.2 ± 1.8 14 1.9 ± 1.9 15 1.6 ± 1.4 15 1.7 ± 1.6 12
Platelet survival (%) >.2
Pooled 34.2 ± 16.3 7 38.7 ± 34.2 10 39.2 ± 35.5 9 33.7 ± 30.6 8
Apheresis 44.5 ± 27.3 12 40.5 ± 36.8 14 33.1 ± 29.0 14 33.0 ± 30.1 11
*Significance of t test between the 2 groups at baseline.
†Significance by analysis of variance between the 2 groups at multiple time points (30 minutes and 2, 4, and 24 hours).
Fig 2. A, Blood loss measured in the operating room (OR), blood loss measured in the surgical intensive care unit
(SICU), and combined total blood loss in patients who received liquid-preserved platelet transfusions and in those
who received cryopreserved platelet transfusions. Data are shown as median and IQR. M, Median; Q1, 25th per-
centile; Q3, 75th percentile. B, Volumes of transfused blood products received by the same groups. Data are
shown as mean ± SEM.
A
B
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mination were not significantly different between the
groups. After platelet transfusion, the concentration of
thromboxane B2 in the blood shed at the site of the
bleeding time determination was indeterminately high-
er in the patients receiving the cryopreserved platelets
(P = .068), and this also might have reached statistical
significance with a larger patient cohort (Table IV).
After platelet transfusion, plasma fibrinogen level
was significantly higher in the patients receiving the
cryopreserved platelets than in the patients receiving
the liquid-preserved platelets (Table IV). Serum albu-
min, plasma factors V and VIII, and plasma fibronectin
and D-dimer were not significantly different in the 2
patient groups (Table IV).
Table V demonstrates that no differences were noted
in the hematocrit, platelet count, mean platelet volume,
platelet increment, platelet survival, and bleeding time
according to whether pooled or apheresed platelets
were transfused.
Blood loss and transfusion requirements. The
intraoperative blood loss recorded after the administra-
tion of protamine accounted for 30% and 29% of the
total blood loss in the patient groups receiving liquid-
preserved and cryopreserved platelet transfusions,
respectively (Fig 2). Blood loss after heparin reversal
with protamine was lower in patients transfused with
cryopreserved platelets than in patients transfused with
liquid-preserved platelets (Fig 2, A). The median total
blood loss in the patients receiving the cryopreserved
platelet transfusions was 1721 mL, with an interquar-
tile range (IQR) of 1118 mL. In the patients receiving
the liquid-preserved platelet transfusions, the median
total blood loss was 2298 mL and the IQR was 1639
mL (P = .007). Because the total surgical intensive care
unit blood loss could be contaminated by serous, non-
sanguineous drainage from the chest, an analysis was
performed in which the blood loss during only the first
8 hours after protamine administration was analyzed
(not shown in Fig 2, A). There again was significantly
less total blood loss in the patients receiving cryopre-
served platelets (median 1093 mL, IQR 566 mL, vs
1443 mL, IQR 1251 mL, in the patients receiving liq-
uid preserved platelets, P = .05). Blood loss did not dif-
fer according to whether the patient received liquid-
Fig 3. A, Blood loss measured in the operating room (OR), blood loss measured in the surgical intensive care unit
(SICU), and combined total blood loss in patients who received liquid-preserved pooled platelet transfusions and
in those who received liquid-preserved apheresed platelet transfusions. Data are shown as median and IQR. M,
Median; Q1, 25th percentile; Q3, 75th percentile. B, Volumes of transfused blood products received by the same
groups. Data are shown as mean ± SEM.
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preserved apheresed or liquid-preserved pooled plate-
lets (Fig 3, A).
To ensure that the increase in blood loss observed in
the patients who received the liquid-preserved platelet
transfusions was not due to the higher number of
patients undergoing valve replacement (with or without
coronary artery bypass grafting) in this group (12 vs 6
patients in the cryopreserved group), the analyses were
repeated after exclusion from the liquid-preserved
group of the 6 patients who had the longest duration of
CPB. The average duration of CPB in the resultant 23
patients receiving liquid-preserved platelet transfusions
was 161 ± 57 minutes. This was not significantly dif-
ferent (P = .4) from the average CPB duration of 159 ±
69 minutes in the 23 patients receiving cryopreserved
platelet transfusions. The blood loss, however,
remained significantly higher in the patients receiving
the liquid-preserved platelet transfusions (total median
blood loss in the latter 2329 mL, IQR 1715 mL, vs
1830 mL, IQR 979 mL, in the patients receiving cry-
opreserved platelet transfusions, P = .0089).
The volume of blood products used was lower in
Fig 4. In vitro procoagulant activities of fresh, liquid-preserved, and cryopreserved platelets. Liquid-pre-
served platelets were stored in the blood bank for 3 to 4 days before assay. Procoagulant activity was deter-
mined by flow cytometric analysis of the binding of the activated coagulation factor V–specific monoclon-
al antibody V237. Platelets were stimulated (10 minutes at 37°C) either with thrombin (2 U/mL), collagen
(20 m g/mL), and calcium chloride (3 mmol/L); with calcium chloride (3 mmol/L); or with buffer alone (No
Agonist). Values were expressed as the percentage of maximal V237 binding, as determined by the effect on
fresh platelets of the calcium ionophore A23187 (40 m mol/L) and calcium chloride (3 mmol/L). Data are
shown as mean ± SEM. Asterisk indicates P < .05 for comparison between cryopreserved platelets and fresh
platelets stimulated with the same agonist. Comparisons between liquid-preserved platelets and fresh
platelets were not significantly different.
Table VI. Results of in vitro platelet function studies
Liquid-preserved at 22°C
Fresh 24 h 48 h 72 h Cryopreserved
Mean ± SD n Mean ± SD n Mean ± SD n Mean ± SD n Mean ± SD n P* P†
pH 7.06 ± 0.06 20 7.25 ± 0.10 20 7.33 ± 0.12 20 7.33 ± 0.14 18 6.81 ± 0.15 24 <.001 <.001
Hypotonic stress response (%) 70 ± 25.0 7 79 ± 18.4 8 78 ± 7.7 8 76 ± 13.1 6 28 ± 13.3 23 <.001 <.001
Platelet aggregation (DU) 256 ± 59 20 201 ± 57 20 189 ± 78 18 169 ± 85 20 140 ± 31 25 <.001 .083
TXB2 per platelet (pg · 10–6) 310 ± 188 20 191 ± 220 20 122 ± 127 20 115 ± 92 16 440 ± 254 25 <.001 <.001
Liquid-preserved platelets were all apheresis units. TXB2, Thromboxane B2; DU, digitizer units.
*By analysis of variance.
†Difference between 72-hour liquid-preserved and cryopreserved platelets, by t test.
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patients transfused with cryopreserved platelets than in
patients transfused with liquid-preserved platelets (Fig
2, B). The analysis of the blood products transfused was
also repeated after exclusion of the 6 patients undergo-
ing valve replacement in the liquid-preserved group
who had the longest duration of CPB. The mean ± SD
of the total volume of blood products transfused (not
shown in Fig 2) continued to be significantly higher in
the patients who received the liquid-preserved platelet
transfusions than in those who received the cryopre-
served platelet transfusions (3426 ± 1963 mL vs 1933
± 1042 mL, P = .0012). Fig 3, B, also shows that
patients transfused with liquid-preserved pooled
platelets received more platelets, fresh-frozen plasma,
and total blood products than did the patients who were
transfused with liquid-preserved apheresed platelets.
These statistical analyses of blood loss and transfu-
sion requirements were repeated without the exclusion
of any patient (analysis by intent to treat). Statistically
significant differences continued to be observed
between the 2 types of platelet transfusion. Log trans-
formation of the data resulted in P = .04 for the differ-
ence in blood loss between the 2 groups and P = .008
for the difference in blood product transfusion between
the 2 groups.
In vitro function of fresh, liquid-preserved, and
cryopreserved platelets (Table VI). The in vitro stud-
ies were performed on platelets obtained from healthy
volunteers. The pH of cryopreserved platelets was sig-
nificantly lower (P < .0001) than the pH of fresh
platelets; this in turn was significantly lower (P <
.0001) than the pH of the liquid-preserved platelets.
Likewise, the response to hypotonic stress was marked-
ly lower in the cryopreserved platelets than in either the
fresh (P = .003) or the liquid-preserved platelets (P <
.0001). Platelet aggregation after cryopreservation was
reduced with respect to that of the fresh platelets (P <
.0001); it was not significantly different from platelet
aggregation after 72 hours of liquid preservation.
In contrast, stimulation of cryopreserved platelets
with AA and ADP resulted in plasma levels of throm-
boxane B2 that were significantly higher than those in
platelets stimulated after 72-hours of liquid preserva-
tion (P < .001). In addition, cryopreserved platelets had
more surface procoagulant activity than either liquid-
preserved platelets stored at 22°C for 3 to 4 days or
fresh platelets (Fig 4): 6.6% ± 2.7% of maximum for
cryopreserved platelets versus 0.9% ± 0.5% of maxi-
mum for liquid-preserved platelets versus 0.7% ± 0.3%
of maximum for fresh platelets. Stimulation of the
platelets either with a combination of thrombin, colla-
gen, and calcium chloride or with calcium chloride
alone also resulted in significantly greater procoagulant
activity on the surfaces of the cryopreserved platelets
than on the surfaces of the liquid-preserved platelets
(Fig 4).
Discussion
Bleeding during and after cardiac operations is relat-
ed to 2 causes: (1) the surgical incision that cuts into
blood vessels and vascularized tissues (surgical bleed-
ing) and (2) defects in hemostasis that prevent normal
clotting and that are amplified by the conditions of
CPB.2,3 This latter type of bleeding can be considered
nonsurgical because it does not originate from a spe-
cific anatomic incision or tear. Properly quantified,
nonsurgical blood loss has been used as a clinical tool
for the assessment of the hemostatic efficacy of phar-
macologic interventions.12,22 In this prospective ran-
domized study, a specific effort was made to quantify
nonsurgical blood loss. In contrast to most other stud-
ies, which only measured the blood lost through the
chest tubes in the surgical intensive care unit, the mea-
surement of blood loss in this study was started in the
operating room after complete reversal with protamine
of the effects of heparin. During the ensuing period of
chest closure, all the blood oozing from the tissues,
including the blood contained in the sponges, was col-
lected and accurately measured by a trained research
assistant. Surgical mishaps occurring during this period
and resulting in excessive surgical blood loss were
prospectively identified, and affected patients were
excluded from analysis. Patients brought back to the
operating room for control of excessive postoperative
bleeding were also excluded.
The nonsurgical blood loss was significantly lower in
the patients receiving the cryopreserved platelets than
in the patients receiving the liquid-preserved platelets
(Fig 2, A), although the risk profiles of the 2 groups
were similar. This difference was accompanied by a
significant, if transient, increase in the postoperative
hematocrit in the former group (Table IV) and by a sig-
nificant reduction in the amount of blood products
transfused (Fig 2, B).
The reduction in the postoperative blood loss seen in
the patients receiving cryopreserved platelet transfu-
sions probably reflects better in vivo hemostatic func-
tion of the cryopreserved platelets compared to the liq-
uid-preserved platelets. Nonsurgical blood loss after
CPB has been recognized as a good indicator of hemo-
static function in the comparative assessment of the
efficacy of hemostatic drugs in patients undergoing
cardiac operations.22 Furthermore, although the post-
operative bleeding times were not different in the 2
patient groups in this study, the level of thromboxane
B2 in the blood shed at the bleeding time determination
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site was higher in the patients receiving the cryopre-
served platelets than in those receiving the liquid-pre-
served platelet transfusions. This difference ap-
proached but did not reach statistical significance
because of the relatively small sample size in which
this measurement was performed. An increased ability
of platelets to generate thromboxane at the bleeding
time site has been shown to be a reliable measure of the
platelets’ in vivo hemostatic effect.21,23
This study was not designed to investigate the effects
of liquid-preserved pooled and those of liquid-pre-
served apheresed platelet transfusions separately
because the administration of these liquid-preserved
platelet transfusions was predicated on the availability
of either type in the blood bank. When the results for
these 2 types of liquid-preserved platelet transfusions
were analyzed separately, however, patients who
received the liquid-preserved pooled platelet transfu-
sions were found to have required a significantly high-
er volume of blood products after the operation than
did patients who received liquid-preserved apheresed
platelets (Fig 3, B). This was due in part to the higher
volumes transfused with the pooled platelets. There
was also a tendency for the blood loss to be higher in
the patients who received the liquid-preserved pooled
platelet transfusions (Fig 3, A). The small sample size
and poor statistical power, however, precluded this
study from making a definitive statement about the
merits of liquid-preserved pooled platelets versus liq-
uid-preserved apheresed platelets.
In this study decreased blood loss was demonstrated
in the patients receiving cryopreserved platelets despite
the facts that smaller numbers of cryopreserved
platelets had been transfused (Table II) and the post-
transfusion platelet increment was decreased in the
patients receiving cryopreserved platelet transfusions
(Table IV). The decrease in platelet survival that was
observed in the patients receiving the cryopreserved
platelets approached statistical significance and corrob-
orated previous studies demonstrating inferior platelet
survival with cryopreservation.24,25 These findings con-
firmed in the setting of CPB data from a previous study
of healthy volunteers receiving aspirin that indicated
that the in vivo hemostatic effect of transfused platelets
did not correlate with their survival in the circulation.10
It is clear from this study that the decreased in vivo sur-
vival did not interfere with the ability of the cryopre-
served platelets to reduce blood loss after CPB.
Compared with standard liquid-preserved platelets,
cryopreserved platelets have been reported to have
reductions in function in vitro, including adhesive
capacity,8 stimulus-response coupling,7 aggregation,5,7
and granule release.5,6 They have also been found to
have lower pH levels25 and more morphologic abnor-
malities. This study also showed an adverse effect of
cryopreservation on in vitro quality of the platelets, as
assessed by 3 commonly used tests. Platelet aggregation
in response to AA and ADP was lower in the cryopre-
served platelets than in the liquid-preserved platelets.
The pH of the milieu of the cryopreserved platelets was
lower than that of the liquid-preserved platelets, and the
recovery from hypotonic stress, which has been shown
to correlate with in vivo platelet recovery,26 was also
less in the cryopreserved than the liquid-preserved
platelets. These in vitro tests did not correlate with the
superior in vivo effect of the cryopreserved platelets that
was shown by their ability to reduce blood loss after
CPB.
This study also assessed the thromboxane production
and the procoagulant activities of liquid-preserved and
cryopreserved platelets, and the results of these in vitro
tests did correlate with in vivo hemostatic function.
Cryopreserved platelets generated more surface proco-
agulant activity than did liquid-preserved platelets.
Formation of a procoagulant surface for the assembly
of the coagulation system is an important function of
platelets in the hemostatic process.27 Cryopreserved
platelets also generated more thromboxane than did
liquid-preserved platelets. Thromboxane A2, a meta-
bolic product of AA, causes vasoconstriction and
platelet aggregation.28 Through these mechanisms, the
additional generation of thromboxane by cryopre-
served platelets is likely to have reduced blood loss
from the site of injury. Additional studies are needed to
determine the mechanisms through which cryopreser-
vation of platelets increases in vitro procoagulant activ-
ity and thromboxane production and improves in vivo
hemostatic function.
In our study, patients receiving the cryopreserved
platelet transfusions had a significantly shorter dura-
tion of postoperative intubation. This difference could
not be explained by variables measured in this study.
Possibly the shorter intubation reflects an improvement
in pulmonary vascular permeability related to a salu-
tary effect of cryopreserved platelets on endothelial
integrity. Johnson and associates29 have reported that
maintenance of endothelial integrity is among the func-
tions of platelets.
This study shows the following: (1) Cryopreserved
platelet transfusions are superior to liquid-preserved
platelets in reducing nonsurgical blood loss and the need
for blood product transfusions after CPB. (2) The reduc-
tion in nonsurgical blood loss seen in the patients receiv-
ing cryopreserved platelet transfusions probably reflects
improved in vivo hemostatic function of cryopreserved
platelets after CPB. (3) Some in vitro measures of platelet
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quality (aggregation, pH, hypotonic stress) may not re-
flect the in vivo quality of platelet transfusions after
CPB, whereas other in vitro measures (platelet procoag-
ulant activity and thromboxane) do reflect this.
We greatly appreciate the efforts and advice of Dr Michael
Crittenden. We also acknowledge Mheir Doursounian,
Michael Zolkewitz, Gina Ragno, Maria Hansson-Wicher, and
Stephanie McCarter in the completion of this study.
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Appendix
Platelet cryopreservation method. In brief, apheresed
platelets were collected with a continuous-flow centrifuga-
tion system (Fenwal CS 3000, with the PLT chamber or the
TNX-6 chamber; Baxter Healthcare, Deerfield, Ill). Anti-
coagulant citrate dextrose (ACD) was used as the anticoagu-
lant at a ratio of 1 volume of ACD to between 8 and 11 vol-
umes of blood. A 50 to 75 mL volume of 27% dimethyl
sulfoxide in saline solution was added to the platelets con-
tained in the 1000 mL polyvinyl chloride platelet-freezing
bag system (Fenwal 4R2986) to achieve a final dimethyl sul-
foxide concentration of 6%. The platelets were placed in an
aluminum container, frozen at a rate of 2° to 3°C/min, and
then stored at –80°C in a mechanical freezer. Platelets were
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collected and frozen at University of Massachusetts Medical
Center (Worcester, Mass) and then transported frozen,
packed in dry ice, to the Naval Blood Research Laboratory
(Boston), where they were stored at –80°C. As needed, the
frozen platelets from each ABO type were transported, again
on dry ice, to the West Roxbury Veterans Administration
Medical Center, where they were stored at –80°C in a mech-
anical freezer until they were thawed, washed, resuspended,
and stored in ACD plasma at 22°C for as long as 5 hours
before infusion.
Liquid-preserved platelets. Pooled platelets were pre-
pared from units of whole blood collected into citrate-phos-
phate-dextrose anticoagulant that had been stored at room
temperature for no longer than 8 hours before platelet isola-
tion. The whole blood was centrifuged (2000g for 3 minutes)
and the platelet-rich plasma was expressed into the attached
transfer pack. The platelet-rich plasma was then centrifuged
(5000g for 5 minutes) and all but 35 to 70 mL of the platelet-
poor plasma was expressed into the second transfer pack. The
concentrated platelets were stored undisturbed at 22°C for 1
hour before resuspension. The resuspended platelets were
stored in CLX bags in incubators maintained at 22° ± 2°C
with rotation for as long as 5 days before pooling. No longer
than 4 hours before use, 5 to 7 units of platelets of the same
ABO group were pooled in a 300-mL transfer pack or 8 to 10
units were pooled in 600-mL transfer pack.
Apheresed platelets were collected with a continuous-flow
centrifugation system (Fenwal CS3000 with PLT chamber).
ACD (National Institutes of Health formula A) was used as
the anticoagulant at a ratio of 1 volume of ACD to 10 vol-
umes of blood. The apheresed platelets were stored for as
long as 5 days in 300 mL plasma in 1000-mL CLX plastic
bags* in incubators maintained at 22° ± 2°C with rotation.
Platelet aggregation in response to arachidonic acid
and adenosine diphosphate.15 In vitro studies were done
with fresh, liquid-preserved, and previously frozen apheresis
products. The platelet count for the in vitro testing was
adjusted to 5.0 · 108/mL with autologous platelet-poor-plas-
ma and measured with an automated particle counter (Coulter
Model JT). A 50 m L combination of 0.5 mg/mL AA and 20
m mol/L ADP was added to 450 m L diluted platelets (final
concentrations 50 m g/mL AA and 2 m mol/L ADP). The
platelet aggregation pattern was recorded for 5 minutes. The
patterns were analyzed by digitizing the area under the curve
with the Kurta Is/ONE input system (Kurta Corp, Phoenix,
Ariz) and the data were reported as digitizer units for the 5-
minute period of aggregation.
Thromboxane B2 assay.21 Thromboxane B2 was measured
with a commercially available radioimmunoassay (New
England Nuclear, Boston, Mass). Baseline levels of throm-
boxane were measured in the cell-free plasma, prepared by
centrifuging a 450-m L sample with 50 m L of saline solution
and 0.02 ng/mL ibuprofen at 1650g for 10 minutes. The cell-
free plasma samples were frozen at –80°C until assay. In addi-
tion, production of thromboxane B2 per platelet was measured
in the supernatant after aggregation with a combination of 50
m g/mL AA and 2 m mol/L ADP. After 5 minutes of aggrega-
tion, ibuprofen (0.02 ng/mL final concentration) was added to
the cuvette to arrest thromboxane production and the sample
was placed on ice. The sample was then centrifuged (1650g at
4°C for 10 minutes) and the plasma was frozen at –80°C until
assay as described previously. The thromboxane production
per platelet was calculated as follows:
Thromboxane production per platelet (pg) = (Aggregated
thromboxane B2 value [pg] – Baseline thromboxane B2 value
[pg]) / (Platelet count) / 0.1 mL
Platelet recovery from hypotonic stress.25 Platelet counts
were measured with an automated particle counter (Coulter
model JT). Response of the platelets to hypotonic stress was
determined with a Philips PU 8800 UV/VIS spectrophotome-
ter (Philips Electronic Instruments, Inc, Mahwah, NJ). Both
test and reference positions of the spectrophotometer were
zeroed at the same time with 600 m L cell-free plasma and 300
m L saline solution. A 600-m L sample of the diluted apheresis
product and a 300-m L volume of saline solution were placed
in the test position and baseline optical density was recorded.
A second 600-m L sample of apheresis product and a 300-m L
volume of water were placed in the test position and the opti-
cal density was recorded for 10 minutes. Percentage recovery
from hypotonic stress was calculated as follows:
Recovery from hypotonic stress (%) = [(Secondary decrease
in transmittance for 10 minutes) / (Initial increase in trans-
mittance)] · 100%
Plasma pH. Nondiluted platelet pheresis product samples
were kept in sealed plastic test tubes at 22°C until the pH mea-
surement was made. Measurements were made on an Orion
SA (model 520A) pH meter (Orion Research, Inc, Boston,
Mass) equipped with an Omega silver–silver chloride electrode
(Omega PHB-G2; Omega Engineering, Inc, Stamford, Conn).
Procoagulant activities of fresh, liquid-preserved, and cry-
opreserved platelets. This determination was performed as
previously described elsewhere.30 Procoagulant activity was
determined by flow cytometric analysis of the platelet bind-
ing of the coagulation factor V–specific monoclonal antibody
V237. Platelets were stimulated (10 minutes at 37°C) either
with thrombin (2 U/mL), collagen (20 m g/mL), and calcium
chloride (3 mmol/L), with calcium chloride (3 mmol/L), or
with buffer alone. Values were expressed as the percentage of
maximal V237 binding, as determined by the effect on fresh
platelets of the calcium ionophore A23187 (40 m mol/L) and
calcium chloride (3 mmol/L).
*CLX = Tri(2)-ethylhexyl trimellitate (Cutter Laboratories, Berkeley,
Calif).
